Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
NCT02513667 · University of Texas Southwestern Medical Center · PHASE2 · terminated · last registry update 2023-02-03 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated after UTSW was informed by Novartis that further support for the study would not be provided” | Open Targets' class: business administrative | Registry record, University of Texas Southwestern Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALK in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-13Also stopped (withdrawn): SCRI Development Innovations, LLC, Lorlatinib + Cisplatin or Carboplatin (NCT05948462)
- 2023-11-21Results posted on the registry: National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2023-11-20Phase 3 first posted: Bristol-Myers Squibb, Repotrectinib + Crizotinib (NCT06140836)
- 2023-10-13Phase 3 first posted: Shenzhen TargetRx Co., Ltd., TGRX-326 + Crizotinib (NCT06082635)
- 2023-08-14Phase 3 first posted: Medicine Invention Design, Inc, ALECENSA - alectinib hydrochloride capsule (NCT05987956)
- 2023-07-07Also stopped (terminated): Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2023-01-27Results posted on the registry: Takeda, Midazolam + Brigatinib (NCT03420742)
- 2023-01-26Results posted on the registry: Criterium, Inc., brigatinib (NCT02706626)
- 2023-01-26Also stopped (terminated): Criterium, Inc., brigatinib (NCT02706626)
- 2022-12-27Also stopped (terminated): University of California, San Francisco, Ceritinib + Trametinib (NCT03087448)
- 2022-10-24Results posted on the registry: University of Colorado, Denver, Brigatinib (NCT04634110)
- 2022-10-24Also stopped (terminated): University of Colorado, Denver, Brigatinib (NCT04634110)
- 2022-10-17Also stopped (terminated): University of California, San Francisco, Binimetinib + Brigatinib (NCT04005144)
- 2022-04-22Phase 3 first posted: Betta Pharmaceuticals Co., Ltd., Ensartinib + Placebo (NCT05341583)
- 2022-02-11Results posted on the registry: University of Colorado, Denver, Crizotinib (NCT03088930)
- 2022-02-09Results posted on the registry: Pfizer, Avelumab + PF-06463922 (NCT02584634)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision